Circle Pharma to Present at the 44th Annual J.P. Morgan Healthcare Conference January 5, 2026 READ MORE
Circle Pharma Announces Nomination of CID-165, an Oral First-in-class Cyclin D1 RxL Inhibitor, as Development Candidate for its Second Oncology Program December 17, 2025 READ MORE
AACR-NCI-EORTC 2025: First-in-class oral macrocyclic cyclin D1-selective inhibitors demonstrate anti-tumor activity in cyclin D1-dependent tumors October 23, 2025 READ MORE
Circle Pharma Unveils First Preclinical Data from Cyclin D1 Program at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics October 23, 2025 READ MORE
Circle Pharma Announces Upcoming Poster Presentation Highlighting the Anti-tumor Potential of Cyclin D1 RxL Inhibition at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics October 14, 2025 READ MORE
